BB Biotech AG

Equities

BION

CH0038389992

Biotechnology & Medical Research

Market Closed - Swiss Exchange 12:30:28 2024-03-28 pm EDT 5-day change 1st Jan Change
45.55 CHF +0.77% Intraday chart for BB Biotech AG -4.61% +6.55%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
BB Biotech's Loss Narrows in FY23; Operating Income Down MT
BB Biotech AG Reports Earnings Results for the Full Year Ended December 31, 2023 CI
BB Biotech Trims FY23 Dividend as Net Loss Narrows MT
BB Biotech Names Successor to Outgoing Chair MT
BB Biotech AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Switzerland's BB Biotech Swings to Q3 Loss; Operating Income Shrinks MT
Tranche Update on BB Biotech AG?s Equity Buyback Plan announced on April 12, 2022. CI
BB Biotech Shares to be Suspended from Euronext Star Milan Pending Delisting MT
BB Biotech AG Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Switzerland's BB Biotech to Scrap Listing on Italian Bourse MT
BB Biotech Logs Decline in H1 Loss, Operating Income MT
Tranche Update on BB Biotech AG?s Equity Buyback Plan announced on April 12, 2022. CI
BB Biotech AG Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Europeans contrasted; gold below USD2,000 threshold AN
Europeans without momentum ahead of PMIs AN
BB Biotech Posts Lower Q1 Loss; Operating Income Falls MT
Tranche Update on BB Biotech AG?s Equity Buyback Plan announced on April 12, 2022. CI
Europeans down; auto sector suffers AN
BB Biotech AG Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Swiss Investor BB Biotech's Loss Shrinks in FY22 MT
Tranche Update on BB Biotech AG?s Equity Buyback Plan announced on April 12, 2022. CI
Mib at more than one-year highs; Tenaris bullish AN
BB Biotech Proposes Lower FY22 Dividend; Net Loss Narrows MT
Mib in the red; Alfonsino splashes among PMIs AN
BB Biotech AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Chart BB Biotech AG
More charts
BB Biotech is a portfolio company that specializes in investments in biotechnology companies. At the end of 2018, the stock portfolio, assessed at market value to be EUR3,064.2 million, breaks down by type of holding as follows: - listed companies (99.9%): primarily Ionis Pharmaceuticals (rare diseases), Gilead Sciences (infectious viral diseases and flu), Celgene Corporation (cancer and inflammation of the immune system), Esperion Therapeutics (cardio-metabolic diseases), Vertex Pharmaceuticals (infectious diseases and diseases of the immune system) and Incyte (cancers, hematologic disorders and inflammatory diseases); - other (0.1%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
45.55 CHF
Average target price
47.7 CHF
Spread / Average Target
+4.72%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock BB Biotech AG - Swiss Exchange
  4. News BB Biotech AG
  5. BB Biotech Proposes Lower FY22 Dividend; Net Loss Narrows